We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Portable Device Developed for Cancer Detection

By LabMedica International staff writers
Posted on 13 Sep 2011
A hand held low-cost device is being developed to diagnose cancer especially for limited-resource settings. More...


The analyzer is operated using mobile electronic devices and performs genetic analysis on micro-ribonucleic acids (miRNAs) which are single-stranded molecules that regulate genes. Changes in certain miRNAs and other genetic marker have been linked to cancer and other health-related issues.

Scientists at Michigan State University (MSU; East Lansing, MI, USA) have developed the genetic analyzer called the Gene-Z which has the capability to screen for established markers of cancer very inexpensively in the field. As it is a hand-held device operated by a solar charged battery, it is particularly useful in limited-resource settings found in the developing world. In addition to cancer detection, the Gene-Z device also is being developed to diagnose routine tuberculosis (TB) and drug-resistant TB, determine human immunodeficiency virus (HIV) levels during treatment and monitor overall antibiotic resistance.

The Gene-Z has been tested using an iPod Touch (Apple Inc., Cupertino, CA, USA) or Android-based tablets (Open Handset Alliance; Mountain View, CA, USA). Syed Hashsham, PhD, a professor at MSU collaborated with Reza Nassiri, MD, PhD, director of MSU's Institute of International Health, to establish connections with physicians worldwide. Prof. Hashsham said, "Gene-Z has the capability to screen for established markers of cancer at extremely low costs in the field, because it is a hand-held device operated by a battery and chargeable by solar energy, it is extremely useful in limited-resource settings."

Prof. Nassiri added, "Until now, little effort has been concentrated on moving cancer detection to global health settings in resource-poor countries. Early cancer detection in these countries may lead to affordable management of cancers with the aid of new screening and diagnostic technologies that can overcome global health care disparities." The Gene-Z device was presented at the US National Institutes of Health's Cancer Detection and Diagnostics Conference, which took place August 22-23, 2011, in Bethesda (MD, USA).

Related Links:
Michigan State University
Apple Inc.
Open Handset Alliance


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: Schematic overview of the CRISPR-Assisted Nanodroplet-pairing Platform for Differential Identification of NTM (CANDI). The platform combines broad-range amplification using conserved regions of the 16S and 23S rRNA genes with species-specific CRISPR recognition. Fluorescence-coded CRISPR droplets are paired with sample droplets containing amplified products, enabling multiplexed target recognition and signal decoding (Image Credit: Yiwen Yang, Jingsong Xu, Dakang Xu)

Nanodroplet CRISPR Technology Supports Rapid, Multiplexed Mycobacterial Identification

Mycobacterial infections are difficult to diagnose because closely related species can have different clinical and therapeutic implications. Nontuberculous mycobacteria (NTM) are increasingly recognized... Read more

Industry

view channel
Image: TruVerus is designed to deliver a broad menu of routine blood tests from a small blood sample on a single, automated benchtop platform (Photo courtesy of Truvian Health)

Collaboration Advances Automated Benchtop Platform for Routine Blood Testing

Routine blood testing is central to clinical decision-making, but access can vary across laboratory and healthcare settings. Broader use of automated benchtop platforms may help integrate testing more... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.